Table 3 Summary of SPR1NT results and other SMA studies and cohortsa

From: Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial

  

Onasemnogene abeparvovec

Nusinersen

Symptomatic patients

Presymptomatic children

Presymptomatic children

 

PNCR14

STR1VE-US36

STR1VE-EU37

SPR1NT, two-copy cohort

SPR1NT, three-copy cohort

NURTURE,b two-copy cohort30

NURTURE,b three-copy cohort30

Intention-to-treat population, n

23

22

32

14

15

15

10

SMN2 copies

2

2

2

2

3

2

3

Median (range) age at diagnosis, days

N/A

67 (56–126)c

76 (26–156)

8 (1–14)

8 (2–26)

N/A

N/A

Median (range) age at infusion, days

N/A

105 (15–177)

123 (54–180)

21 (8–34)

32 (9–43)

19 (8–41)

23 (3–42)

Baseline median (range) CHOP INTEND

32.5 (31–33)d

33.5 (18–52)

28.0 (14–55)

48.5 (28–57)

N/A

45.0 (25–60)

53.5 (40–60)

Baseline median (range) CMAP amplitude, mVe

0.3 (0.04–1.1)

N/A

N/A

3.9 (2.1–6.1)

4.1 (2.7–7.0)

3.2 (1.1–9.7)

4.0 (0.2–7.0)

Sitting independently by 18 months, n (%)f

0

14 (64)

14 (44)

14 (100)

N/A

N/A

N/A

Sitting independently by 24 months of age, n (%)f

0

N/A

N/A

N/A

14 (93)

15 (100)

10 (100)

Standing independently by 18 months of age, n (%)f

0

1 (5)

1 (3)

11 (79)

N/A

N/A

N/A

Standing independently by 24 months of age, n (%)f

0

N/A

N/A

N/A

15 (100)

9 (60)

10 (100)

Walking independently by 18 months of age, n (%)f

0

1 (5)

1 (3)

9 (64)

N/A

N/A

N/A

Walking independently by 24 months of age, n (%)f

0

N/A

N/A

N/A

14 (93)

9 (60)

10 (100)

Alive without permanent ventilation at 18 months of age, n (%)f

6 (26)g

20 (91)

31 (97)

14 (100)

15 (100)

15 (100)

10 (100)

  1. HINE-2, Hammersmith Infant Neurological Examination section 2; N/A, not available.
  2. aThere are no published head-to-head studies of onasemnogene abeparvovec and nusinersen. Differences in trial design, including primary endpoints, how endpoints were measured, and eligibility criteria, make direct comparison of results from these studies infeasible. The PNCR measured CHOP INTEND; NURTURE measured WHO and HINE-2 criteria; and STR1VE-US and STR1VE-EU measured WHO criteria and CHOP INTEND.
  3. bNURTURE results represent interim analysis at data cut of 29 March 2019. At the time of this analysis, the median age of the infants was 34.8 months (range, 25.7–45.4)26.
  4. cMedian (range) is reported as the interquartile range.
  5. dValue obtained for patients with symptom onset <3 months of age, including seven patients with two SMN2 copies and one patient with three SMN2 copies
  6. eUlnar CMAP amplitude recorded from the abductor digiti minimi muscle at baseline for the PNCR and NURTURE studies and peroneal CMAP amplitude recorded from the tibialis anterior muscle for SPR1NT.
  7. fMilestones were evaluated over different observation periods between studies and included 18 months for STR1VE-US, STR1VE-EU, and SPR1NT two-copy cohort; 24 months for the SPR1NT three-copy cohort; and a median follow-up time of 35 months for NURTURE.
  8. gSurvival without permanent ventilation at 14 months.
Back to article page